Health Trials

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease

ConditionProteinuric Kidney Disease
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age10-65
SponsorVertex Pharmaceuticals Incorporated

About this trial

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apolipoprotein L1 (APOL1)-mediated proteinuric kidney disease.

Eligibility criteria

Qualifiers

APOL1 genotype of G1/G1, G2/G2, or G1/G2

Proteinuric kidney disease

Disqualifiers

Solid organ or bone marrow transplant

Uncontrolled hypertension

History of diabetes mellitus

Known underlying cause of kidney disease including but not limited to sickle cell disease

Trial design

Treatments tested in this trial

  • VX-147
  • Placebo

Treatment groups

466 Participants
are divided into 3 treatment groups

Sponsors and collaborators

Vertex Pharmaceuticals Incorporated

Lead sponsor

Source ClinicalTrials.gov